All News

Life sciences therapies are moving away from a one-size-fits-all approach to a targeted approach using a patient's own genetic information and immune system to treat previously incurable diseases.

Outside of raising prices, pharma can generate new revenue from just three other sources, write Tom Kottler.

Click the title above to open the Pharmaceutical Executive April 2019 issue in an interactive PDF format.

Declaring it a “strategic sector for priority development,” China has opened up the floodgates for sweeping reforms of the nation’s healthcare infrastructure-a watershed moment for the Chinese pharmaceutical and healthcare industries, where all stakeholders will have to adapt to the new rules of the game.

Regulatory Affairs Professionals Society's Executive Director, Paul Brooks, discusses the looming uncertainty about what will happen after the UK leaves the European Union as many important details remain unclear.

Patient preferences are increasingly seen as valuable in healthcare policy decision-making, but such studies are not always easy to design and implement, writes Nick Hicks.

The discrepancies between trial and real-life patient conditions are such that Real-World Evidence (RWE) can be utilized to supplement this process.

The FDA planned budget features added funds allotted to improved oversight of drugs, biologics, and medical devices.

As part of FDA’s ongoing effort to modernize interactions with industry, FDA launched a portal to help with submissions of controlled correspondence via email instead of manual data entry.

Michael J. Hennessy Jr., president of MJH Associates‚ Inc., answers questions about the acquisition of UBM Life Sciences media brands and his company’s perspective on the evolving biopharma landscape.

We’re about to lose the most tech-savvy FDA chief in recent memory, writes Pratap Khedkar.

Brenda Snow talks to Pharm Exec about the creation of Snow Companies, the first full-service agency to bring strategic, regulatory-compliant, real-life patient stories to direct-to-patient initiatives.

Click the title above to open the Pharmaceutical Executive March 2019 issue in an interactive PDF format.

After a prolonged period of relative stagnation, the strategically influential, clinically rich French life sciences market suddenly seems to be rediscovering its mojo-thrusting the pharma and medtech sectors into the spotlight.

Purdue Pharma and its corporate leadership featured prominently in the media recently as litigation mounts over their sales and marketing of Oxycontin. Nir Kossovsky offers some observations about the lessons this situation provides for all corporate leaders responsible for their companies’ reputations.

New HHS proposal would remove the current safe harbor protection from the federal Anti-Kickback Statute for rebates or discounts provided to Medicare Part D drug plans and certain state Medicaid programs.

Click the title above to open the Pharmaceutical Executive February 2019 issue in an interactive PDF format.